Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

ClinicalTrials.gov ID: NCT00230789

Public ClinicalTrials.gov record NCT00230789. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multiphase, Single Arm, Open Label Study To Evaluate The Effects Of Tolterodine ER In Conjunction With Behavioral Intervention On Subject Satisfaction And Over- Active Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects Who Were Dissatisfied With Their Most Recent Antimuscarinic OAB Medication Therapy.

Study identification

NCT ID
NCT00230789
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
417 participants

Conditions and interventions

Interventions

  • Tolterodine ER 4 mg QD Drug
  • OAB Patient Behavioral Training Material Behavioral

Drug · Behavioral

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Jan 26, 2021

2005 – 2006

United States locations

U.S. sites
51
U.S. states
22
U.S. cities
51
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona
Pfizer Investigational Site Sun Lakes Arizona
Pfizer Investigational Site Little Rock Arkansas
Pfizer Investigational Site Beverly Hills California
Pfizer Investigational Site Buena Park California
Pfizer Investigational Site Mission Viejo California
Pfizer Investigational Site Modesto California
Pfizer Investigational Site Oceanside California
Pfizer Investigational Site Paramount California
Pfizer Investigational Site Sacramento California
Pfizer Investigational Site Torrance California
Pfizer Investigational Site Tustin California
Pfizer Investigational Site Colorado Springs Colorado
Pfizer Investigational Site Wheat Ridge Colorado
Pfizer Investigational Site Hallandale Florida
Pfizer Investigational Site Orlando Florida
Pfizer Investigational Site Wellington Florida
Pfizer Investigational Site Woodstock Georgia
Pfizer Investigational Site Libertyville Illinois
Pfizer Investigational Site Mattoon Illinois
Pfizer Investigational Site Newton Kansas
Pfizer Investigational Site Milford Massachusetts
Pfizer Investigational Site Manchester Missouri
Pfizer Investigational Site St Louis Missouri
Pfizer Investigational Site Westhampton New Jersey
Pfizer Investigational Site Albuquerque New Mexico
Pfizer Investigational Site Albany New York
Pfizer Investigational Site Endwell New York
Pfizer Investigational Site Garden City New York
Pfizer Investigational Site Poughkeepsie New York
Pfizer Investigational Site The Bronx New York
Pfizer Investigational Site Greensboro North Carolina
Pfizer Investigational Site Hickory North Carolina
Pfizer Investigational Site Raleigh North Carolina
Pfizer Investigational Site Canton Ohio
Pfizer Investigational Site Zanesville Ohio
Pfizer Investigational Site Norman Oklahoma
Pfizer Investigational Site Abington Pennsylvania
Pfizer Investigational Site Bala-Cynwyd Pennsylvania
Pfizer Investigational Site Camp Hill Pennsylvania
Pfizer Investigational Site Philadelphia Pennsylvania
Pfizer Investigational Site Williamsport Pennsylvania
Pfizer Investigational Site Mt. Pleasant South Carolina
Pfizer Investigational Site Simpsonville South Carolina
Pfizer Investigational Site Bartlett Tennessee
Pfizer Investigational Site Johnson City Tennessee
Pfizer Investigational Site New Tazewell Tennessee
Pfizer Investigational Site Houston Texas
Pfizer Investigational Site Provo Utah
Pfizer Investigational Site Mountlake Terrace Washington
Pfizer Investigational Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00230789, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00230789 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →